Ann Richmond, Ph.D., is an Ingram Professor of Cancer Research and Professor of Pharmacology and Dermatology at Vanderbilt University School of Medicine. A major question her lab is investigating is "What is the role of the inflammatory response in tumor progression". They are studying the role of proteins that promote the migration of inflammatory cells into tissues. These "chemotactic" proteins can educate leukocytes to either stimulate or inhibit tumor progression. These factors can also stimulate the growth of the tumor and recruit blood vessels into the tumor to provide a continuous supply of nutrients to feed tumor growth. They have tested how pharmaceutical drugs that shut down the inflammatory process and alter the expression of genes that recruit inflammatory cells into the tumor microenvironment effect tumor progression. They are also evaluating how to deliver therapies that teach the patient's leukocytes to fight the growth of the tumor and switch from a pro-tumorigenic to an anti-tumorigenic state.

They have learned that the inflammatory process, combined with other genetic and environmental factors, contributes to mutations in genes that regulate the growth of cells. Some of these mutations make the cells capable of continuous growth and enable the cancer cells to spread throughout the body and grow in distant organs. By determining what genes become mutated or amplified in each patient's tumor and then providing therapies that specifically inhibit the activity of that mutated or amplified gene, we can deliver "personalized cancer treatment" that addresses the problem in that persons specific cancer. This works so much better than the "one size fits all" approach often used previously in chemotherapy. Recently they have determined that inhibition of aurora kinases or cyclin dependent kinases 4 and 6 induce tumor cells to undergo senescence and when these kinases are inhibited while at the same time other drugs are added that activate the tumor suppressor p53 or the death receptor DR5, melanoma cells die and tumors regress. The Richmond Lab is also interested in evaluating how therapeutic agents that target driver mutations such as PI3K, RAS or BRAF affect the tumor microenvironment and the immune response to the tumor. They postulate that in some instances drug resistance comes in part due to deleterious effects of the therapy on the tumor microenvironment. Dr. Richmond collaborate with medical oncologists, surgical oncologists, bioengineers, cellular and molecular biologists, and scientists in pharmaceutical companies to address the scientific questions we are asking. This TEAM interaction enables us to optimize our studies to make important breakthroughs in tumor biology and tumor therapy.